ALLAY-HFrEF
Heart Failure with Reduced Ejection Fraction (HFrEF)
Pivotal TrialActive
Key Facts
Indication
Heart Failure with Reduced Ejection Fraction (HFrEF)
Phase
Pivotal Trial
Status
Active
Company
About Alleviant Medical
Alleviant Medical is an innovative, clinical-stage medical device company pioneering a no-implant interatrial shunt therapy for heart failure. Its core technology, the Alleviant System, is a catheter-based device that creates a small, pressure-relieving passage between the heart's atria, aiming to improve symptoms and quality of life for patients who remain symptomatic despite optimal medical therapy. The company is advancing its technology through two pivotal clinical trials and operates as a pre-revenue, private entity backed by venture capital. If successful, Alleviant's implant-free approach could differentiate it in the growing market for heart failure interventional devices.
View full company profileTherapeutic Areas
Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | FDA Approved / PMA |
| Neucardin® | Zensun Sci & Tech | Phase 2/3 |
| Cardiac Contractility Modulation (CCM) Implant | Berlin Heals | Pre-clinical / Early Clinical |
| SRD001 (inferred) | Sardocor | Phase 1 |
| Undisclosed HFrEF Program | NanoPhoria Bioscience | Preclinical |
| AC01 | AnaCardio | Phase 2 |
| Firibastat | Quantum Genomics | Phase II |
| Omecamtiv Mecarbil | Cytokinetics | Phase 3 |